SRR12696742
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.500
- MYC_TARGETS_V1+0.500
- OXIDATIVE_PHOSPHORYLATION+0.500
- CHOLESTEROL_HOMEOSTASIS+0.400
- FATTY_ACID_METABOLISM+0.400
- PROTEIN_SECRETION+0.400
- ADIPOGENESIS+0.300
- ANDROGEN_RESPONSE+0.300
- DNA_REPAIR+0.300
- G2M_CHECKPOINT+0.300
Top 10 suppressed
- ANGIOGENESIS-0.200
- KRAS_SIGNALING_DN-0.200
- NOTCH_SIGNALING-0.200
- WNT_BETA_CATENIN_SIGNALING-0.200
- APICAL_JUNCTION-0.100
- HEDGEHOG_SIGNALING-0.100
- IL6_JAK_STAT3_SIGNALING-0.100
- INTERFERON_ALPHA_RESPONSE-0.100
- INTERFERON_GAMMA_RESPONSE-0.100
- PANCREAS_BETA_CELLS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD031129_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.842 |
| 2 | SRR13311180 | — | — | 0.840 |
| 3 | TCGA-18-4086-01A-01R-1100-07 | — | cohortSQ2 | 0.835 |
| 4 | TCGA-73-4676-01A-01R-1755-07 | — | cohortA1 | 0.824 |
| 5 | C3N-00574 | — | cohortA4 | 0.824 |
| 6 | 8824c0fd-764e-4525-952b-f25efa742772 | — | — | 0.816 |
| 7 | SJEPD030169_D1.RNA-Seq | EPN | EPN Tumor | 0.816 |
| 8 | 0e1c98de-b4e2-4f42-beca-9948f867a46b | — | — | 0.809 |
| 9 | aMVAC.P_015_TURBT_S235 | — | — | 0.807 |
| 10 | BS_2EN3X6HB | high-grade glioma | — | 0.807 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |